Anixa Biosciences (ANIX) Cash & Equivalents (2010 - 2026)

Anixa Biosciences (ANIX) has 17 years of Cash & Equivalents data on file, last reported at $13.7 million in Q2 2026.

• Quarterly Cash & Equivalents rose 616.54% year-over-year to $13.7 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $13.7 million (up 616.54% YoY) and the FY2025 annual result came in at $15.2 million, down 23.99% from the prior year.
• Cash & Equivalents retreated to $13.7 million in Q2 2026, from $15.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $29.8 million in Q1 2022 to a low of $1.1 million in Q1 2025.
• A 5-year average of $18.5 million and a median of $20.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents slumped 94.69% — and 2026, when it soared 616.54%.
• Tracing ANIX's Cash & Equivalents over 5 years: stood at $29.5 million in 2022, then fell by 19.64% to $23.7 million in 2023, then declined by 15.8% to $20.0 million in 2024, then retreated by 23.99% to $15.2 million in 2025, then retreated by 9.81% to $13.7 million in 2026.
• The last three Cash & Equivalents figures came in at $13.7 million (Q2 2026), $15.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.